A study for a 22 year old woman who takes Xeljanz - from FDA reports

Summary

447 females aged 22 (±5) who take the same drug are studied. This is a personalized study for a 22 year old female patient who has Colitis Ulcerative. The study is created by eHealthMe based on reports from FDA.



How the study uses the data?

The study is based on gender, age, active ingredients of any drugs used. Other drugs that have the same active ingredients (e.g. generic drugs) are considered.

What are the drugs?

What are the conditions?

How to use the study?

Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.


On Mar, 15, 2019

447 females aged 22 (±5) who take Xeljanz are studied.


Number of reports submitted per year:

Xeljanz for a 22-year old woman.

Information of the patient in this study:

  • Age: 22
  • Gender: female
  • Conditions: Colitis Ulcerative
  • Drugs taken:
    • Xeljanz (tofacitinib citrate)

eHealthMe real world results:

Most common side effects over time

< 1 month:
  1. Drug ineffective
  2. Pain
  3. Weakness
  4. Insomnia (sleeplessness)
  5. Drug effect decreased
  6. Impaired work ability
  7. Fatigue (feeling of tiredness)
  8. Haemoglobin decreased
  9. Confusion
  10. Depression
1 - 6 months:
  1. Drug ineffective
  2. Large intestine perforation (hole in large intestine)
  3. Drug hypersensitivity
  4. Fatigue (feeling of tiredness)
  5. Panic disorder
  6. Abortion missed (delayed or silent miscarriage)
  7. Abdominal pain
  8. Rashes (redness)
  9. Lip pain
  10. Hospitalisation
6 - 12 months:
  1. Drug ineffective
  2. Unintended pregnancy (unwanted pregnancies as well as those that are mistimed)
  3. Weight decreased
  4. Pulmonary tuberculosis (lungs tuberculosis)
  5. Disseminated tuberculosis
  6. Abortion induced (medically referred abortion)
  7. Joint swelling
  8. Mood swings (an extreme or rapid change in mood)
  9. Joint pain
  10. Nausea and vomiting
1 - 2 years:
  1. Drug ineffective
  2. Pulmonary embolism (blockage of the main artery of the lung)
  3. Crohn's disease (condition that causes inflammation of the gastrointestinal tract)
  4. Nausea and vomiting
  5. Diarrhea
  6. Unintended pregnancy (unwanted pregnancies as well as those that are mistimed)
  7. Phobia (fear)
  8. Headache (pain in head)
2 - 5 years:
  1. Feeling abnormal
5 - 10 years:
n/a
10+ years:
n/a
not specified:
  1. Fatigue (feeling of tiredness)
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Arthropathy
  4. Hypersensitivity
  5. Abdominal discomfort
  6. C-reactive protein increased
  7. Rhinorrhea (watery mucus discharge from the nose)
  8. Injection site reaction
  9. Memory loss
  10. Nasopharyngitis (inflammation of the nasopharynx)

Top conditions involved for these people *:

  1. Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 19 people, 4.25%
  2. Alopecia Areata (patchy baldness that typically begins with rapid hair loss): 18 people, 4.03%
  3. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 14 people, 3.13%
  4. Birth Control : 10 people, 2.24%
  5. Crohn's Disease (condition that causes inflammation of the gastrointestinal tract): 9 people, 2.01%
  6. Hair Loss : 9 people, 2.01%
  7. Pain : 7 people, 1.57%
  8. Arthritis (form of joint disorder that involves inflammation of one or more joints): 6 people, 1.34%
  9. Preventive Health Care : 6 people, 1.34%
  10. Supplementation Therapy : 5 people, 1.12%

Top co-used drugs for these people *:

  1. Enbrel (118 people, 26.40%)
  2. Humira (53 people, 11.86%)
  3. Plaquenil (53 people, 11.86%)
  4. Actemra (42 people, 9.40%)
  5. Cimzia (33 people, 7.38%)
  6. Arava (29 people, 6.49%)
  7. Remicade (26 people, 5.82%)
  8. Orencia (22 people, 4.92%)
  9. Methotrexate (18 people, 4.03%)
  10. Simponi (12 people, 2.68%)

* Some reports may have incomplete information.

What is next?

You are not alone:




Related studies:



FDA reports used in this study



Recent updates

Recent general studies
Recent personal studies


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.